ArticleCancer immunology, immunotherapy : CII2008
A33 antigen displays persistent surface expression.
Article in Cancer immunology, immunotherapy : CII, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 76 citations in OpenAlex.
- Circulating intestine-derived exosomal miR-328 in plasma, a possible biomarker for estimating BCRP function in the human intestines.Scientific reports · 2016Trial
- 124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2011Trial
- (124)I-huA33 antibody PET of colorectal cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2011Trial
- PreclinicalJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- GPA33-Targeted Trimeric Immunotoxin Exhibits Enhanced Antitumor Activity in Human Colorectal Cancer Xenografts.International journal of molecular sciences · 2026Article
- Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment.Nature reviews. Cancer · 2025Review
- Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a BivalentJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Improving Intracellular Delivery of an Antibody-Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo.Molecular cancer therapeutics · 2024Article
- Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment.Biomolecules · 2023Article
- A review on emerging targeted therapies for the management of metastatic colorectal cancers.Medical oncology (Northwood, London, England) · 2023Review
- Article
- Potential Application of Exosomes in Vaccine Development and Delivery.Pharmaceutical research · 2022Review
- The role of microvesicles as biomarkers in the screening of colorectal neoplasm.Cancer medicine · 2022Article
- Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186.Journal for immunotherapy of cancer · 2022Article
- Recent Advances in the Development of Tetrazine Ligation Tools for Pretargeted Nuclear Imaging.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Novel Diagnostic Biomarkers in Colorectal Cancer.International journal of molecular sciences · 2022Review
- Antibody-Based Immunotoxins for Colorectal Cancer Therapy.Biomedicines · 2021Review
- Inverse electron demand Diels-Alder click chemistry for pretargeted PET imaging and radioimmunotherapy.Nature protocols · 2021Article
- Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using bi-Specific Antibodies and Therapeutic Vaccines.Biological procedures online · 2021Review
- HarnessingProceedings of the National Academy of Sciences of the United States of America · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
The A33 antigen is a cell surface glycoprotein of the small intestine and colonic epithelium with homology to tight junction-associated proteins of the immunoglobulin superfamily, including CAR and JAM. Its restricted tissue localization and high level of expression have led to its use as a target in colon cancer immunotherapy. Although the antigen is also present in normal intestine, radiolabeled antibodies against A33 are selectively retained by tumors in the gut as well as in metastatic lesions for as long as 6 weeks. Accordingly, we have studied the trafficking and kinetic properties of the antigen to determine its promise in two-step, pretargeted therapies. The localization, mobility, and persistence of the antigen were investigated, and this work has demonstrated that the antigen is both highly immobile and extremely persistent-retaining its surface localization for a turnover halflife of greater than 2 days. In order to explain these unusual properties, we explored the possibility that A33 is a component of the tight junction. The simple property of surface persistence, described here, may contribute to the prolonged retention of the clinically administered antibodies, and their uncommon ability to penetrate solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.